MedTrace Logo

Vasoactive Intestinal Peptide in COPD

NCT00464932 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 34

Last updated 2007-04-24

No results posted yet for this study

Summary

This study, a new immunomodulatory therapy of COPD with vasoactive intestinal peptide (VIP) was evaluated. Based on preliminary unpublished clinical and experimental results, the course of disease under VIP treatment and the molecular mechanisms involved were assessed.

34 patients with severe COPD were treated either with VIP inhalation in addition to conventional therapy or inhalation of placebo plus conventional therapy for a period of 3 months. The trial was conducted as a double blind, comparative study with two parallel groups.

Conditions

  • COPD
  • Pulmonary Hypertension

Interventions

DRUG

Vasoactive Intestinal Peptide (VIP)

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Lutz-Henning Block, MD · Medical University of Vienna, Department of Pulmology

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2006-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00464932 on ClinicalTrials.gov